Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A composition for wound healing and use thereof

A technology for wounds and uses, applied in drug combinations, medical preparations containing active ingredients, gene therapy, etc., can solve the problems of diabetic foot ulcers being easily infected and unable to be cured, etc.

Active Publication Date: 2009-11-11
BLUE BLOOD BIOTECH CORP
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Diabetic foot ulcers are so easily infected that they sometimes don't heal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A composition for wound healing and use thereof
  • A composition for wound healing and use thereof
  • A composition for wound healing and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Example 1: Effect of TMD23 on migration of HaCaT epidermal cells

[0078] The effect of TMD23 on the migration of HaCaT cells was examined using a Boyden chamber with a 6.5 mm diameter polycarbonate filter membrane (8-μm pore size). Collagen type IV is coated on the surface of the lower filter membrane. Add TMD23 (100 ng / ml) or TMD23 (100 ng / ml) and anti-TM antibody (1 μg / ml) to DMEM in the lower well. Each upper well was added with 1 × 10 4 cell suspension (50 μL). Eight hours later, fixed with methanol and stained with 10% GIEMSA, the number of cells migrated through the membrane was counted under a microscope. Such as figure 1 As shown, TMD23 significantly induced the chemotactic migration of HaCaT cells.

Embodiment 2

[0079] Example 2: Materials

[0080] DMAp is 100 μg recombinant TMD23 purified protein (SEQ ID NO. 1 ) dissolved in 20 μl 0.5% CMC / PBS solution. 0.5% CMC (carboxymethylcellulose) / PBS (phosphate buffered saline) (pH 7.4) was used as a vehicle for DMAp and CGS-21680 solutions. CGS-21680 hydrochloride (2-p-[2-carboxymethyl]anilino-5'-N-ethylcarboxamidoadenosine), a G protein activator, was purchased from Sigma-Aldrich.

[0081] DMAc gel is 100 μg recombinant TMD23 purified protein (SEQ ID NO. 1 ) dissolved in 20 mg base gel. The basic gel above was used as a negative control for DMAc gel and Regranex gel. The above basic gel is composed of sodium carmellose, sodium chloride, sodium acetate trihydrate, glacial acetic acid, methylparaben, propylparaben, m-cresol 1-lysine hydrochloride, benzyl alcohol , methylchloroisothiazoline (methylchloroisothiazoline), methylisothiazoline (methylisothiazoline), ammonium acryloyldimethyltaurate / VP copolymer (ammoniumacryloyldimethyltaurate / ...

Embodiment 3

[0084] Example 3: Animals

[0085] CD-1 (Crl.) male mice weighing 24±2 g were provided by Taiwan BioLasco (licensed by Charles River Laboratories). A space of 29 x 18 x 13 cm was partitioned for 10 mice. All mice were kept in MDS Medical Service Company (Taiwan laboratory is preferred) for at least one week, maintaining a 12-hour light-dark cycle and controlled temperature (22°C-24°C) and humidity (50%-60%) environment. Standard laboratory mouse chow [MF-18 (Oriental Yeast Co., Ltd., Japan)] and RO water were freely available. Work including housing construction, experiments, and animal handling were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Academies Press, Washington D.C., 1996).

[0086] Non-insulin-dependent diabetic (NIDDM) male mice (C57BLKS / J-m+ / +Lepr db) weighing 50±5 g (9 weeks old) provided by the Institute of Animal Reproduction (IAR, Japan) were used. These mice all showed hyperinsulinemia, hyperglycemia and is...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for treatment of wound healing, comprising administering to a patient in need of such treatment with an effective amount of a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin. The invention also relates to a composition for the use of accelerating wound healing, comprising a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin.

Description

technical field [0001] The present invention relates to methods and compositions for accelerating wound healing. Background technique [0002] Angiogenesis and Thrombomodulin [0003] While several molecules are known in the art as therapeutic agents for the treatment of important vascular abnormal coagulation diseases and disorders, there remains a need to provide compositions and disorders useful in the treatment of these diseases and diseases and disorders that are symptomatic of abnormal angiogenic activity. method. Such diseases include cardiovascular diseases such as hypotension, hypertension and arteriosclerosis; stroke, heart attack and thrombosis after angioplasty; angiogenic diseases; respiratory conditions such as pulmonary fibrosis and asthma; tumor cell invasion tumor-related diseases such as angiogenesis and metastasis; wound healing and coagulation disorders, and reproductive dysfunction such as premature uterine contractions and impotence. [0004] A numb...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/18A61K9/08A61K9/06A61K9/10A61K48/00A61P17/02
CPCA61K48/00A61K38/366A61K38/36A61P17/02A61P3/10A61K38/16A61K38/00
Inventor 江传箕苏辉斌吴华林施桂月
Owner BLUE BLOOD BIOTECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com